Standard chemotherapy has a poor outcome in adult patients with high-risk acute lymphoblastic leukaemia (ALL). Allogeneic haematopoietic stem cell transplant (alloSCT) is the treatment of choice, and SCT with alternative progenitors should be considered in the absence of a matched sibling donor. There is great heterogeneity in the data on unrelated SCT for adult patients with high-risk ALL. Many studies include both paediatric and adult patients, or provide combined data from ALL and acute myeloid leukaemia (AML) patients.
For many years, bone marrow has been the stem cell source of choice for unrelated transplants. However, the mobilised peripheral blood stem cell (PBSC) has been widely adopted by many centres as the preferred unrelated stem cell source. Some data have pointed out a worse prognosis for patients receiving PBSC versus bone marrow graft in the unrelated setting for ALL 34, 35 due to a higher incidence of chronic graft- For patients in first CR, the OS (95% confidence interval [CI] ), relapse rate and TRM at two years were 40% (13%), 6% (7%) and 54% (13%), respectively. These data included patients from an early period (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , but more recent reports incorporating high-resolution typing HLA methods for HLA-A, -B and -C have shown better expected survival in the USCT setting with a decreased TRM. 14,37 A large experience with 169 adult patients with Philadelphia-chromosome-negative (Phi -) ALL in first CR reported a 38% DFS probability, with a 20% TRM and a 42% relapse rate at five years. The most important factors determining poor survival besides the degree of HLA mismatch and T-cell depletion were a white blood cell count >100x10 9 /l, more than eight weeks to attain CR and CMV seropositivity. The analysis of 1,874 unrelated bone marrow transplantations under the auspices of the NMDP showed that lowresolution mismatches have a more severe impact on survival than mismatches detectable only with high-resolution typing techniques. 38 Moreover, the impact of a mismatch at a particular locus depended on the total number of mismatches between donor and recipient 39 with the T-cell undepleted grafts. The adverse impact of mismatch on unrelated donor stem cell transplant (UD-SCT) outcome was especially marked in patients without advanced malignancy.
Unrelated Cord Blood Stem Cell Transplant
Unrelated cord blood was initially introduced as an alternative source for SCT for paediatric patients, but more recently it has been considered for adult patients. 17 Initial experiences with unrelated cord blood stem cell transplant (UCB-SCT) showed the importance of receptor age, the cell dose infused and the degree of HLA disparity in transplant outcome.
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Cord blood progenitors are more permissive with HLA disparities, and it is standard practice to allow zero to two HLA mismatches using lowresolution typing methods for HLA-A and -B and high-resolution molecular typing for HLA-DRB1. In contrast, recommendation for unrelated bone marrow or PBSC transplants is more restrictive and considers zero to one mismatch using high-resolution molecular typing of eight or 10 allelles (HLA-A, -B, -C, -DRB1, -DP). The use of highresolution HLA typing by sequencing for HLA-A, -B, -C and -DQ has
shown that the degree of mismatching in UCB-SCT is even higher than expected. However, it does not seem to have a significant impact on the long-term clinical outcome in the UCB-SCT setting.
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Comparison of Outcome Between Unrelated Donor Transplant and Unrelated Cord Blood Transplant
Many studies have described the outcome of UCB-SCT and compared the results with those from UD-SCT. In most studies comparing the two sources, the proportion of patients with more advanced disease or with poor-prognosis leukaemia was higher in the UCB-SCT group.
Moreover, some studies included both AML and ALL or a variable proportion of paediatric patients. Finally, the OS, DFS and TRM were estimated at different periods of time (one to five years or more) and a short period follow-up underestimated late TRM (see Table 1 ). Most comparative studies of UCB-SCT versus bone marrow SCT for leukaemia from UDs have shown similar outcomes.
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Initial comparisons between UCB-SCT and UD-SCT (including only bone marrow SCT) showed that patients receiving an UCB-SCT had a delayed neutrophil and platelet engraftment and a lower incidence of acute GvHD, in spite of a greater HLA mismatch between the patient and the graft. 18, 19 However, the survival rate was similar when a comparison of procedures was performed at an early stage for transplants with cord blood progenitors in adult patients. Three major studies have compared the outcome of paediatric patients with ALL after USCT, focusing on the haematopoietic stem cell source. [42] [43] [44] In paediatric patients, a better outcome for patients receiving a fully matched UD bone marrow transplant has been reported, and this was confirmed by some groups in an adult population. 19 In terms of adult patients, Atsuta et al. 45 carried out a large study using the Japanese registries to explore the impact of stem cell source (bone marrow or umbilical cord) for adult patients with acute leukaemia, making a disease-specific comparison. In the ALL group, there were no differences in terms of TRM, OS or DFS when eight out of eight matched bone marrow or UCB were compared. There was a trend towards a higher cumulative incidence of relapse in UCB recipients. As expected, UCB-SCT was associated with a lower incidence of chronic (especially extensive) and acute GvHD. The recurrence of the primary disease was the leading cause of death for high-risk ALL patients.
Other studies did not find differences in relapse rate when UCB-SCT and UD-SCT were compared. [18] [19] [20] 45 The disadvantages of using UCB as a haematopoietic source are the limited number of stem cells in the unit, the impossibility of performing cellular therapy with lymphocytes belonging to the donor, the delayed haematological recovery and the delayed immune reconstitution.
However, a higher infectious vulnerability may be compensated by a lower risk of GvHD. 18, 46 Due to slower haematopoietic and immune reconstitutions after UCB-SCT, severe infections are more frequent after UCB-SCT than after non-T-cell-depleted progenitors in UD-SCT,
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especially within 100 days after transplantation. 19, 47, 48 Parody et al. 48 extensively compared the infectious events in UCB-SCT and UD-SCT, and concluded that UCB-SCT recipients had a similar risk of death due to infection if an accurate selection of the cord blood unit was performed. With a median follow-up of three years, UCB-SCT recipients had a higher risk of developing any severe infection (85 versus 69% in bone marrow/peripheral blood SCT recipients). However, at three years the risks of severe bacterial infection or other infections were similar in the UCB-SCT and UD-SCT. In addition, the 100-day and three-year incidences of infection-related mortality did not differ among groups.
In contrast to the adult setting, UCB-SCT seems to present a similar risk of serious infections than unmanipulated bone marrow in the paediatric population. 49 A higher stem cell dose has shown to improve the outcome of acute leukaemia patients receiving SCT with progenitors from unrelated bone marrow (nucleated cells [NC] >3.65x10 8 /kg) 31 or umbilical cord blood (NC >2x10 7 /kg). 17 In contrast, in UCB-SCT, the importance of an HLA match has been less evident in many reports than that of cell dose. 46 The HLA disparity will be only partially compensated by the progenitor cellular dose, 18, 19, 49 and in some studies may be associated with a lower risk of leukaemia relapse. However, in UCB-SCT, even if the procedure is not so greatly compromised by HLA disparity, this will also be associated with a poorer outcome due to a higher risk of GvHD and TRM without any survival advantage. 18, 19, 31, 38, 41 In most studies, a favourable disease status at transplant was the most important factor affecting outcome, rather than the type of stem cell source or donor type in patients with ALL. [18] [19] [20] 30, 33, 45, 50, 51 In high-risk ALL patients in first CR without a fully compatible donor, transplant from a donor with an acceptable degree of mismatch or from UCB may allow early and effective treatment, thereby avoiding the risk of disease progression during a prolonged search for a fully matched donor.
Newer strategies to decrease TRM in UCB-HSCT, such as the thirdparty infusion, 52 infusion of two partially HLA-matched UCB 53 or intrabone UCB administration, 54,55 could be explored in the future. In the UD-HSCT setting, the generalised high-resolution typing methods 38 and more efficient transmission of data from the donor registries will in the future allow to improve the clinical outcome of patients with a highrisk ALL who lack a sibling donor.
Unrelated Transplants for High-risk Adult Acute Lymphoblastic Leukaemia In some groups, SCT with RIC has been followed by a double or multiple graft for UCB-SCT, a procedure that seems to be associated with a slightly higher incidence of GvHD and a possible improvement of the GvL effect. 61 In vivo T-cell depletion is the most effective method for preventing GvHD after alloSCT, and in spite of a delayed immunological reconstitution this effect could decrease the TRM in USCT. 62 In addition, the T-cell depletion of the graft has been associated with a higher incidence of CMV and fungal infection in the unrelated bone marrow setting, and as thymoglobulin is commonly given as conditioning therapy for UCB-SCT patients, this could contribute to a high incidence of infections in UCB-SCT. On the other hand, as T-cell depletion could also contribute to relapse, this procedure is not routinely performed in high-risk ALL patients.
Graft-versus-leukaemia Effect
In ALL, the antileukaemic activity of GvHD has been traditionally considered weaker than for other haematological diseases. However, many authors 12, 22, 24, [61] [62] [63] [64] 
Conclusions
An alternative donor SCT should be considered for poor-prognosis adult 
